Megestrol Acetate Dosing for Appetite Stimulation in Late 80s Hospice Patient
For a hospice patient in their late 80s seeking appetite restoration, start with megestrol acetate oral suspension 400 mg once daily, which can be increased to 800 mg daily if needed after 2-4 weeks if no response is seen.
Recommended Dosing Strategy
The NCCN Palliative Care guidelines specifically recommend megestrol acetate 400-800 mg/day for patients with weeks-to-months life expectancy who identify increased appetite as an important quality of life goal 1. This aligns with the evidence showing:
- Starting dose: 400 mg daily - This represents the lower end of the effective range and balances efficacy with safety concerns particularly relevant to elderly patients 1
- Maximum dose: 800 mg daily - Can be escalated to this dose if appetite improvement is inadequate after 2-4 weeks 1, 2
- Lower doses (160-200 mg) are insufficient - Studies demonstrate higher doses (400-800 mg) show superior weight gain and appetite improvement compared to lower doses 3, 2
Evidence Supporting This Approach
The 2020 ASCO guideline meta-analysis of 3,428 cancer patients showed megestrol acetate improved appetite (RR 2.57), weight (RR 1.55), and quality of life (RR 1.91) compared to placebo, with higher doses demonstrating greater benefit 3.
In elderly patients specifically, a randomized trial of recently hospitalized patients (mean age 83) found that 400 mg and 800 mg doses significantly increased prealbumin levels (a nutritional marker), while 200 mg did not show benefit over placebo 2.
Critical Safety Considerations for This Age Group
You must counsel the patient and family about serious risks before initiating therapy:
- Thromboembolic events: 1 in 6 patients develop blood clots (RR 1.84) 3, 1
- Increased mortality risk: Meta-analysis showed increased death risk (RR 1.42) 3
- Edema: Common, occurring in approximately 1 in 7 patients (RR 1.36) 3
- Adrenal suppression: At 400-800 mg doses, 70-78% of elderly patients develop cortisol suppression, though clinical adrenal insufficiency symptoms are rare 2
- Delirium risk: Particularly relevant in the very elderly 1
Practical Implementation
Timing: The liquid suspension should be given once daily. Some studies used twice-daily dosing (e.g., 200 mg BID = 400 mg total), but once-daily dosing improves compliance 4.
Response timeline: Appetite improvement typically occurs within 2 weeks if the medication will be effective 5. Weight changes take longer, usually 4-8 weeks 2, 5.
Duration of trial: At least 2 months is considered adequate to determine efficacy per FDA labeling 6, though in hospice patients with limited prognosis, reassess at 2-4 weeks.
When Megestrol May Not Be Appropriate
Given the 1 in 23 mortality risk and 1 in 6 thromboembolic risk 1, carefully reconsider megestrol if:
- Life expectancy is days to weeks (dying patient phase) - risks may outweigh benefits
- History of thromboembolic disease
- Significant edema already present
- Goals shift away from appetite as a quality of life priority
Alternative Considerations
If megestrol is contraindicated or ineffective, the guidelines suggest:
- Dexamethasone 2-8 mg/day - shorter duration of benefit but faster onset 1
- Olanzapine 5 mg/day - may be combined with megestrol for enhanced effect 1
- Mirtazapine 7.5-30 mg at bedtime - particularly if depression contributes 1
The combination of olanzapine 5 mg plus megestrol 400-800 mg showed superior outcomes (85% vs 41% achieving ≥5% weight gain) in one trial 3.